Holdings of Saturn V Capital Management LP
16 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 86.4 % of the equity sleeve
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 87.1 %
- FR 12.9 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | US | 15 | 406.9M $ | 87.07 % |
| 2 | FR | 1 | 60.4M $ | 12.93 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Alumis Inc | 3,202,075 | 70.5M $ | |
| 2 | Amylyx Pharmaceuticals Inc | 4,349,885 | 60.5M $ | |
| 3 | Abivax SA | 542,696 | 60.4M $ | |
| 4 | Vaxcyte Inc | 824,532 | 47.9M $ | |
| 5 | Immix Biopharma Inc | 3,693,585 | 33.6M $ | |
| 6 | Celcuity Inc | 281,904 | 32.2M $ | |
| 7 | Disc Medicine Inc | 449,926 | 28.8M $ | |
| 8 | X4 PHARMACEUTICALS INC | 6,456,646 | 26.7M $ | |
| 9 | Cogent Biosciences Inc | 626,635 | 24.1M $ | |
| 10 | Monopar Therapeutics Inc | 345,626 | 18.9M $ | |
| 11 | Dyne Therapeutics Inc | 966,609 | 17.5M $ | |
| 12 | Invivyd Inc | 10,949,084 | 14.2M $ | |
| 13 | Candel Therapeutics Inc | 2,896,588 | 14.2M $ | |
| 14 | Ovid therapeutics Inc | 4,166,666 | 9.2M $ | |
| 15 | Inhibikase Therapeutics Inc | 3,863,445 | 6.5M $ | |
| 16 | Alto Neuroscience Inc | 88,999 | 2M $ |